Literature DB >> 1556944

Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis.

N Hattori1, H Kurahachi, K Ikekubo, T Ishihara, K Moridera, M Hino, Y Saiki, H Imura.   

Abstract

We determined serum growth hormone-binding protein (GHBP), insulin-like growth factor-I (IGF-I), and growth hormone (GH) levels in patients with cirrhosis and in age-matched control subjects, and investigated their relationships. Serum GHBP levels in cirrhotic patients (14.6% +/- 3.9%) (means +/- SD) were significantly lower than those in normal subjects (20.4% +/- 4.7%). GHBP levels had positive correlations with cholinesterase (r = .58, P less than .001) and Normotest (r = .66, P less than .001), both of which represent liver function in cirrhotic patients. Basal GH levels in cirrhotic patients (range, 0.35 to 13.0 micrograms/L; median, 3.9 micrograms/L) were significantly higher than those in normal subjects (0.015 to 6.0 micrograms/L; 0.19 microgram/L). GHBP levels in cirrhotic patients correlated positively with IGF-I levels (r = .39, P less than .01), and negatively with GH levels (r = -.33, P less than .01). These results may indicate that the serum GHBP level reflects the number of hepatic GH receptors, and that the high basal GH level observed in cirrhotic patients is, at least in part, attributable to decreased clearance of GH by these receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1556944     DOI: 10.1016/0026-0495(92)90071-h

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

1.  Effect of IGF-I on total serum antioxidant status in cirrhotic rats.

Authors:  M García-Fernández; I Castilla-Cortázar; M Díaz-Sánchez; F Díez Caballero; A Castilla; A Díaz Casares; I Varela-Nieto; S González-Barón
Journal:  J Physiol Biochem       Date:  2003-06       Impact factor: 4.158

Review 2.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

3.  Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?

Authors:  A Gaudio; A Lasco; N Morabito; M Atteritano; C Vergara; A Catalano; W Fries; A Trifiletti; N Frisina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 4.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

5.  Decreased IGF-I bioavailability after ethanol abuse in alcoholics: partial restitution after short-term abstinence.

Authors:  S Röjdmark; K Brismar
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

6.  Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis.

Authors:  A Cemborain; I Castilla-Cortázar; M García; B Muguerza; G Delgado; M Díaz-Sánchez; A Picardi
Journal:  J Physiol Biochem       Date:  2000-06       Impact factor: 4.158

Review 7.  Metabolic bone disease in patients with liver disease.

Authors:  Elizabeth Carey; Vijayan Balan
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 8.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

9.  Hematotesticular barrier is altered from early stages of liver cirrhosis: effect of insulin-like growth factor 1.

Authors:  Inma Castilla-Cortazar; Nieves Diez; Maria Garcia-Fernandez; Juan-Enrique Puche; Fernando Diez-Caballero; Jorge Quiroga; Matias Diaz-Sanchez; Alberto Castilla; Amelia-Diaz Casares; Isabel Varela-Nieto; Jesus Prieto; Salvador Gonzalez-Baron
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

10.  Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis.

Authors:  Raquel Pérez; María García-Fernández; Matías Díaz-Sánchez; Juan E Puche; Gloria Delgado; Marian Conchillo; Jordi Muntané; Inma Castilla-Cortázar
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.